Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cinrebafusp alfa
- Development stage
- Phase 2
- Lead developer
- Pieris Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Cinrebafusp alfa (PRS-343) is a bispecific fusion protein designed for immuno-oncology applications, particularly in HER2-positive cancers. It consists of a 4-1BB-targeting Anticalin protein fused to a HER2-targeting antibody, enabling the drug to bridge and cluster T cells at the site of HER2-expressing tumor cells. This localizes 4-1BB activation within the tumor microenvironment, enhancing T cell proliferation and cytotoxic activity while minimizing systemic toxicity. Cinrebafusp alfa has demonstrated clinical benefit and an acceptable safety profile in patients with previously treated HER2-positive malignancies, including gastric cancer. The drug has received orphan drug designation for gastric cancer and is being evaluated in phase II trials for this indication[3][4][6][7].
- Other names
- HER2/4-1BB bispecific
02
Targets
TNFRSF9 (CD137 extracellular domain)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on cinrebafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cinrebafusp alfa.